Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$9.63
$0.18(2.38%)
At close: 4:00 PM EDT
$9.63
$0.18(2.38%)
Day’s Range― - ―
52-Week Range$2.24 - $12.06
Previous CloseN/A
Volume400.70K
Average Volume (3M)2.77M
Market Cap
$1.51B
Enterprise Value$1.63K
Total Cash (Recent Filing)$201.14M
Total Debt (Recent Filing)$3.68M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Nov 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding171,614,010
10 Day Avg. Volume2,927,577
30 Day Avg. Volume2,774,684
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.57Price Target Upside40.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$4.74M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayThe $201.1 million cash and securities balance materially extends operating capacity into the second half of 2028. This gives AbSci time to advance clinical programs, reach important proof-of-concept milestones, and develop its platform without immediate financing pressure.
Promising Early Clinical ProfileA favorable early safety profile and long estimated half-life could support convenient dosing and improve the commercial potential of ABS-201 if efficacy is confirmed. The pharmacokinetic result also provides a foundation for advancing the program into proof-of-concept and Phase 2 studies.
AI-enabled Discovery EfficiencyA substantial reduction in library size can make biologic discovery more efficient by lowering experimental burden and accelerating lead identification. If repeatable across programs, this platform capability may improve development productivity and strengthen AbSci’s value to partners.
Bears Say
Small, Declining Revenue And Heavy LossesRevenue remains far below the cost base, while large accounting losses translate into substantial cash consumption. Without meaningful revenue growth, milestone realization, or product commercialization, AbSci may remain dependent on financing and face a prolonged path to sustainable profitability.
Clinical Efficacy And Durability UnprovenThe current evidence supports safety and pharmacokinetics but does not yet establish that ABS-201 produces meaningful or durable clinical benefits. Failure to demonstrate sufficient hair regrowth or lasting effect in upcoming studies would materially weaken the pipeline’s commercial prospects.
Operating Expenses Remain ElevatedRising R&D and SG&A spending increases the amount of capital required to advance the pipeline while current revenue remains minimal. Although investment may support future development, continued expense growth could accelerate cash burn and make profitability increasingly dependent on successful clinical execution.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.24 and its highest was $12.05 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $1.51B.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Nov 17, 2026 which is in 71 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Aug 11, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.19.
How many shares outstanding does AbSci have?
AbSci has 171,614,010 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went up 0.956%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.57 (40.93% Upside)
$13.57 (40.93% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 67%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $148.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.7%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
267.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AbSci
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
ABSI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive developments: encouraging interim Phase I safety and PK data for ABS-201, a meaningful strategic investment and collaboration with Eli Lilly, a substantial financing that materially strengthened the balance sheet (cash up ~60% quarter‑over‑quarter), clear near‑term clinical milestones, and notable platform efficiency gains (Atlas/Origin). Key risks and negatives are present but limited: efficacy is not yet unblinded, durability remains to be demonstrated beyond 26 weeks, operating expenses increased modestly (~10.2% R&D; ~8.2% SG&A), and successful commercialization depends on Absci's execution despite Lilly's involvement not conferring program rights. Overall, the highlights meaningfully outweigh the lowlights given the strong cash runway, strategic partner validation, and promising PK/safety profile, though clinical proof of efficacy and durability remain the critical upcoming catalysts.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$13.57
▲(40.93% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.04% Insiders
17.60% Mutual Funds
31.41% Other Institutional Investors
24.81% Public Companies and
Individual Investors